证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，公司积极参与JPM等全球医药行业 盛会，密切关注包括脑机接口在内的前沿科技发展动态与行业趋势。相关领域的技术布局将结合公司战 略发展需要审慎研究推进，后续如有实质性进展，公司会及时履行信息披露义务。公司流感创新药壹立 康的医院准入工作正按计划有序推进，目前正积极联动各地渠道与医疗机构，全力加速药品入院落地， 确保药品快速触达临床，更好地满足患者的用药需求。 （文章来源：证券日报） ...

Core Viewpoint - The pharmaceutical industry is entering a new industrial cycle starting in 2025, driven by "innovation" and "going global," which highlights the competitive advantages of Chinese pharmaceutical companies [1][2]. Group 1: Pharmaceutical Industry Insights - Chinese innovative pharmaceutical companies are rapidly gaining global recognition, with License-out transaction upfront payments reaching $8.45 billion in the first 11 months of 2025, surpassing the total for 2024 [3]. - The industry is transitioning into the "BD 2.0 era," which is expected to lead to continuous valuation increases as products enter global registration clinical trials and data readouts [3]. - The small nucleic acid therapies, such as siRNA, represent the "third wave" of modern pharmaceuticals, with market potential projected to grow from $5-10 billion in 2025 to $46.7 billion by 2033 [3]. Group 2: Medical Device Sector - The high-value consumables sector is expected to replicate the industrial trends of innovative pharmaceuticals as the price system stabilizes following the completion of centralized procurement [2][3]. - For instance, leading Chinese companies in surgical robotics are projected to secure 120 new overseas orders by 2025, positioning them among the global leaders, despite their market capitalization being only 1.4% of the global leaders [2][3]. Group 3: Technological Trends - AI in healthcare and brain-computer interfaces are identified as key technological trends reshaping industry competitiveness, with AI being widely applied in imaging diagnostics, pathology analysis, surgical robotics, and smart wearable devices [4]. - The number of approved medical devices for brain-computer interfaces in China has exceeded the total for the previous two years within the first four months of 2025, with B-end procurement volume increasing by 200%, indicating an acceleration in commercialization [4].

文 | 针探局，作者 | 曾可 脑机的伦理问题才是关键。 脑机接口，自踏入2026后，突兀的成为资本市场的新宠。 在部分证券软件统计的概念个股中，"人脑工程"已经有近50家相关企业，分别是涉及脑机安装的医疗器 材类公司、可能涉及脑机制造的消费电子类公司，甚至包括脑机内容提供商、一些软件和游戏公司。 更让人无语的是，连八字都没一撇的事儿，2026年九个交易日内整个板块已经实现超20%的涨幅。总市 值已经突破万亿人民币。 这和马斯克旧事重提有关——最近在一次访谈里，他直白地抛出了个想法：想改写人类的底层代码。他 甚至提出了一个惊人观点：人类有望实现"半永生"，只要能"改写"生命里的既定程序，就能活得更久。 在马斯克的逻辑里，这个"半永生"蓝图分两步走： 第一步靠Neuralink的脑机接口完成"意识捕捉"——往大脑里植入高密度电极阵列，采集神经元信号，最 终生成包含记忆、思维模式的"心智快照"，也就是传统意义上的灵魂。 第二步靠Optimus人形机器人当"意识载体"——让数字化的意识、也就是灵魂有个物理依托，从而实 现"意识转移"。 按照这个思路，等人类身体衰老到极限，就能通过"机械飞升"的方式，让意识以另一种形 ...

Core Viewpoint - The Hong Kong AI healthcare sector experienced a significant adjustment, halting a nine-day winning streak, marking its first decline since 2026. Despite this, the long-term investment logic in AI healthcare remains intact, with opportunities emerging in the oversold bottom range [1][3][11]. Group 1: Market Performance - The Hong Kong AI healthcare index saw a decline, with the Hong Kong Medical ETF (159137) dropping by 2.79% and trading volume significantly reduced to 112 million CNY [1][8]. - Major stocks in the AI healthcare sector faced substantial losses, including Crystal Tech Holdings (2228) down 10.74%, Alibaba Health (0241) down 7.84%, and Ping An Good Doctor (1833) down 4.88% [2][4][10]. Group 2: Market Analysis - Analysts attribute the decline to a phase of valuation correction in the AI healthcare industry, following a period of significant gains and profit-taking behavior in the market [2][10]. - The AI healthcare industry is entering a critical phase of commercialization, driven by a confluence of national strategy and market demand, with current conditions seen as a prime opportunity for new AI healthcare applications [3][11]. Group 3: Future Projections - The global AI healthcare market is projected to reach approximately 26.65 billion USD in 2024, with an expected rapid growth to about 505.59 billion USD by 2033, reflecting a compound annual growth rate of 38.8% [3][11]. - In China, the AI healthcare market is estimated to reach 159.8 billion CNY by 2028, up from 97.3 billion CNY in 2023 [3][11]. Group 4: Investment Recommendations - Citic Securities suggests focusing on five main areas for investment in AI healthcare: AI drug development, grassroots AI healthcare applications, medical data circulation, AI pathology diagnosis, and AI healthcare models [12]. - The Hong Kong Medical ETF (159137) is highlighted as a flexible investment tool, covering key sectors in AI healthcare and related innovations [12].

Group 1 - Several companies have a history of information disclosure issues, including Hangxiao Steel Structure, which faced criminal charges related to insider information leakage, and Aihuilong, which received a warning letter during its IPO phase for disclosure flaws [1] - The information disclosure ratings of three companies have been declining in recent years, with Tianpu Co., Ltd. dropping from a B rating to a D rating, and most companies have low response rates to investors on interactive platforms [1] - In the context of rising market activity and record trading volumes in the A-share market, five companies, including Hangxiao Steel Structure and Tianpu Co., Ltd., have been issued warning letters or are under investigation for inaccurate information disclosure and insufficient risk warnings related to popular concepts like commercial aerospace and artificial intelligence [3] Group 2 - Tianpu Co., Ltd. experienced a significant stock price increase of 16 times by 2025, highlighting the volatility associated with companies linked to trending concepts [3]

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [5]. Core Insights - The medical device industry in China has a prominent supply chain advantage, with overseas markets expected to maintain rapid growth. The brain-computer interface (BCI) sector is at a critical turning point, likely to see demand release. AI medical applications are gradually becoming operational, poised to reshape the health market [3]. Summary by Relevant Sections Investment Recommendations - For the overseas medical device sector, recommended stocks include: United Imaging Healthcare, Nanwei Medical, Microelectronic Physiology, Guichuang Tongqiao, Yuyue Medical, and New Industry. Stocks to watch include: Jingfeng Medical, MicroPort Scientific, and Chuangli Medical [5]. - In the brain-computer interface sector, recommended stocks are: Lepu Medical, Weisi Medical. Stocks to watch include: Meihao Medical, Xiangyu Medical, Mcland, Xinwei Medical, Aipeng Medical, Chengyitong, Chuangxin Medical, and Botuo Bio [5]. - For the AI + device sector, recommended stocks are: Yuyue Medical, BGI Genomics, KingMed Diagnostics, and United Imaging Healthcare. Stocks to watch include: Dian Diagnostics [5]. Overseas Market Growth - The supply chain advantage of domestic medical devices is significant, with exports expected to grow rapidly. In the first three quarters of 2025, United Imaging Healthcare's overseas revenue increased by 41.97% year-on-year, becoming a crucial growth driver for the company. The company continues to expand its market share in key regions due to superior product performance and localized service capabilities. By December 2025, MicroPort Scientific's global cumulative order volume exceeded 160 units, with core products in endoscopy, orthopedics, and vascular intervention surpassing 230 units in total orders. In 2025, Jingfeng Medical achieved a breakthrough in multiple key global markets, leading to explosive growth in overseas orders [5]. Brain-Computer Interface Market - The brain-computer interface market is at a pivotal turning point, with anticipated demand release. China's "14th Five-Year Plan" explicitly suggests a forward-looking layout for future industries, promoting BCI as a new economic growth point. In December 2025, Elon Musk announced that Neuralink would begin large-scale production of BCI devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process. In January 2026, China's BCI company Strong Brain Technology announced it had completed a new round of financing of approximately 2 billion yuan, setting a record for the second-largest single financing in the field globally, following Neuralink. The funds will be used to accelerate core technology research and development, extreme engineering breakthroughs, and product scaling and mass production [5]. AI Medical Applications - AI medical applications are gradually becoming operational, with the potential to reshape the health market. In June 2025, Ant Group launched the AI Health Manager AQ, which was officially upgraded to "Antifufu" in December 2025. By January 2026, the "Antifufu" app had over 30 million monthly active users, with daily inquiries exceeding 10 million, 55% of which came from third-tier cities and below. In January 2026, Tempus AI reported preliminary revenue of approximately 1.27 billion USD for 2025, representing an 83% year-on-year increase, exceeding initial expectations. OpenAI announced the acquisition of the healthcare tech startup Torch to expand into the healthcare sector, while Google launched the next-generation open-source medical AI model MedGemma1.5 and released the open-source medical speech-to-text model MedASR [5].

Core Viewpoint - In the context of rising enthusiasm in the A-share market, five companies have been warned or investigated by regulators for misleading information disclosure related to popular concepts such as commercial aerospace, brain-computer interfaces, and artificial intelligence [1][9]. Group 1: Companies Involved - The five companies involved are Hangxiao Steel Structure, Electric Science Digital, Yahui Long, Yingjixin, and Tianpu Co., which have seen significant stock price increases due to their association with trending concepts [1]. - Tianpu Co. experienced a stock price surge of 16 times by 2025 [1]. Group 2: Regulatory Actions - All five companies have faced regulatory scrutiny for issues such as inaccurate information disclosure and insufficient risk warnings [1]. - Hangxiao Steel Structure has a history of information disclosure violations, including a notable case involving insider information leakage [14]. - Yahui Long had disclosure issues during its IPO phase, leading to a warning from the regulatory body [15]. Group 3: Information Disclosure Ratings - Three of the five companies have seen a decline in their information disclosure ratings, with Tianpu Co. dropping from B to D in 2024, marking it as the lowest-rated among the group [12]. - Electric Science Digital's rating has fallen from A to B over the past two years, indicating a long-term downward trend in disclosure quality [12]. Group 4: Investor Interaction - The average response rate to investor inquiries on the Shanghai Stock Exchange's E-interaction platform varies among the companies, with Electric Science Digital having the highest frequency of responses [10]. - Hangxiao Steel Structure has responded to 708 inquiries since the platform's launch, while Yingjixin has the lowest response rate, averaging one response every 13 days [10].

Group 1 - The A-share market's strong start is supported by incremental capital, with significant net inflows from margin trading and thematic ETFs being the main sources of new funds at the beginning of the year [1] - According to Huatai Securities, the estimated incremental capital scale for 2026 is approximately 2.6 trillion yuan, driven by various sources including low-risk resident funds, high-risk resident funds, foreign capital, long-term funds, and industrial capital [1] - For 2026, it is projected that 60 trillion yuan of one-year or longer fixed deposits will mature, with an increase of 8 trillion yuan compared to 2025, leading to an estimated incremental capital of about 650 billion yuan from low-risk resident funds [1] Group 2 - Shiyun Circuit (603920) is set to benefit from the booming commercial aerospace and brain-computer interface sectors, having achieved full-chain support for low-orbit satellite phased array antennas and is advancing the R&D testing of core components for brain-computer interfaces [2]

Core Viewpoint - The company is actively exploring the application of optical integrated sensors in the non-embedded brain-computer interface field, collaborating with expert teams on research and development [1] Group 1: Company Developments - The company is focusing on the development trends in cutting-edge technology and leveraging its advantages in optical integrated sensor business [1] - The project related to the three-dimensional multimodal sensor is currently in the research and development exploration stage and has not yet generated sales [1] Group 2: Industry Context - The application of optical integrated sensors as human-computer interaction perception devices is being investigated in the brain-computer interface sector [1]

Core Insights - China is at a critical stage for future industry development, with the "14th Five-Year Plan" emphasizing the exploration of diverse technological routes, typical application scenarios, and feasible business models to promote quantum technology, biomanufacturing, and embodied intelligence as new economic growth points [1] Group 1: Future Industry Development Strategies - Local leaders have significantly increased their focus on future industries, with over 700 relevant event information monitored, covering more than 1,700 companies [1] - The development strategies for future industries are becoming clearer, focusing on future manufacturing and future information as core drivers, integrating key technologies like large models and embodied intelligence [1] - Future materials, future energy, and future space are identified as important supports, accelerating breakthroughs in key technologies and practical applications [1] Group 2: Key Future Industries - Future manufacturing emphasizes a dual-drive approach of "technology sourcing + pilot testing" to solidify the foundation of new productive forces [4] - Future information aims to strengthen computing power and expand AI applications, creating a "AI + connectivity + computing power" ecosystem [4] - Future health focuses on the integration of medical and engineering fields, exploring new industrial paths that combine cutting-edge technologies with clinical applications [4] Group 3: Strategic Framework for Future Industries - The strategy highlights localized layouts to solidify the strategic foundation of resource-driven future industries [5] - It advocates for a gradual approach to implement long-term strategies for future industries [5] - The framework emphasizes the importance of innovation services to support disruptive technology sourcing and the creation of an innovative ecosystem [5]